Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-agent depsipeptide in cutaneous T-cell lymphoma
2004-001012-32Phase 2Completed
- Sponsor
- Gloucester Pharmaceuticals
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in cutaneous T-cell lymphoma (CTCL), sponsored by Gloucester Pharmaceuticals. Primary endpoint: Objective disease control rate. Started Nov 2004; status: completed.
02
Drugs
romidepsin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2004-001012-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001012-32.